✨ Free AI Report
Nuo Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Nuo Therapeutics, Inc.
Company Research

Nuo Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Nuo Therapeutics, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Nuo shows genuine market validation through rapid Aurix adoption but faces severe financial constraints that require flawless execution to avoid dilution or restructuring. Strong Q1 2026 revenue growth (169% YoY) and improving gross margins demonstrate traction in the chronic wound care market. However, cash was only $263,827 at March.

What is Nuo Therapeutics, Inc.'s industry? Nuo Therapeutics, Inc. (nuotherapeutics.com) operates in Regenerative Medicine. AskCyborg classifies Nuo Therapeutics, Inc. under Regenerative Medicine in its company registry.

Nuo Therapeutics is a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care. Its primary commercial product is the Aurix System, a point-of-care tech...

4/ 10Mixed

Cyborg Score thesis

Nuo shows genuine market validation through rapid Aurix adoption but faces severe financial constraints that require flawless...

Read the full analyst-debate transcript →
Industry Regenerative Medicine
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Nuo Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Nuo Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Nuo Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Nuo Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Nuo Therapeutics, Inc. Overview

Pro stress-test →

Nuo Therapeutics is a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds. In Q1 2026, total revenues reached approximately $1.3 million, increasing 169% over the prior-year first quarter, with Aurix branded product revenues up over 30% sequentially.

Strategic Profile

Pro stress-test →

Nuo is leveraging Aurix adoption and a Smith+Nephew private-label distribution agreement to drive revenue growth. The market is responding favorably to continued improvement in Medicare-related reimbursement for Aurix and a vastly changed overall reimbursement landscape. However, the company remains pre-profitability with significant financial constraints and ongoing dependence on debt financing to fund growth.

Competitive Landscape

Pro stress-test →

Nuo's Aurix System competes in the autologous PRP therapy market for chronic wound care. Direct competitors include other regenerative medicine and wound care solution providers, though Nuo's point-of-care PRP generation model differentiates it. The improving Medicare reimbursement environment is reducing barriers to adoption, but Nuo remains early-stage relative to larger, well-capitalized wound care competitors with established distribution networks.

Industry Context

Nuo Therapeutics, Inc. operates in Regenerative Medicine.

Key facts

Headquarters: Houston, TX · Revenue: $3.31M TTM · Market cap: $60.7M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Nuo Therapeutics, Inc..

  • Q1 2026 revenues of $1.3M represented 169% growth over Q1 2025, with Aurix branded revenues up 30% sequentially versus Q4 2025.
  • Revenue growth was driven by Aurix adoption, new private-label sales, and $77,941 of Smith+Nephew distribution fee revenue (April 2025 partnership).
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2026Secured $675,000 interim funding and expanded secured debt facility to $2.0 million total at 12% interest payable in warrants
  • May 2026Announced Q1 2026 results showing 169% revenue growth to $1.3 million with narrowing net loss to $446,000
  • +1 moreTrack every material event for Nuo Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Nuo Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ArteriocytePoint-of-care autologous platelet-rich plasma systems for wound care→Vivex BiologicsRegenerative medicine and tissue repair solutions→Smith+Nephew Wound CareAdvanced wound management and regenerative medicine products→

Compare Nuo Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Nuo Therapeutics, Inc. operates in Regenerative Medicine. See how the rest of the sector scores on the Cyborg framework.

Browse Regenerative Medicine research →
NEW · MCP server

Ask your AI assistant about Nuo Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Nuo Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Nuo Therapeutics, Inc. do this quarter?”
“Is Nuo Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Nuo Therapeutics, Inc. do?+
Nuo Therapeutics is a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care. Its primary commercial product is the Aurix System, a point-of-care tech...
What is Nuo Therapeutics, Inc.'s Cyborg Score?+
Nuo Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Nuo Therapeutics, Inc.'s main competitors?+
Named competitors include Arteriocyte, Vivex Biologics, Smith+Nephew Wound Care. The full competitive landscape is in the AskCyborg report.
How can I get the full Nuo Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Nuo Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Nuo Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Regenerative Medicine research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Humacyte, Inc.6TELA Bio, Inc.5Organogenesis Holdings Inc.4Longeveron Inc.